Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $22.25 Consensus PT from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.25.

A number of equities research analysts recently weighed in on CAPR shares. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Saturday, September 27th. B. Riley initiated coverage on shares of Capricor Therapeutics in a research note on Thursday, June 26th. They set a “buy” rating and a $21.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $24.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, September 25th. Finally, Oppenheimer reduced their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, June 23rd.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $4,270,000. Jump Financial LLC bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $1,547,000. Bank of America Corp DE lifted its position in shares of Capricor Therapeutics by 938.9% in the 4th quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company’s stock worth $2,353,000 after buying an additional 154,127 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Capricor Therapeutics by 392.7% in the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company’s stock worth $2,334,000 after buying an additional 134,791 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after buying an additional 116,373 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Trading Down 7.7%

CAPR opened at $7.36 on Friday. The company has a fifty day simple moving average of $7.02 and a 200 day simple moving average of $9.17. The firm has a market cap of $336.50 million, a price-to-earnings ratio of -4.49 and a beta of 0.68. Capricor Therapeutics has a twelve month low of $5.68 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.